← Back to Search
Kinase Regulation Of Human MHC Class I Molecule Expression On Cancer Cells
Elliott J Brea, C. Oh, Eusebio Manchado, Sadna Budhu, Ron S. Gejman, George Mo, P. Mondello, James E Han, Casey A. Jarvis, D. Ulmert, Qing Xiang, Aaron Y. Chang, R. Garippa, T. Merghoub, J. Wolchok, N. Rosen, S. Lowe, D. Scheinberg
Published 2016 · Biology, Medicine
Download PDFAnalyze on Scholarcy
Kinome screens revealed EGFR and MEK as key to reduced MHCI expression on many tumors. FDA-approved inhibitors of these kinases increased surface MHC-I, providing a rationale for clinically testing similar kinase inhibitors with immunotherapies dependent on MHC-I. The major histocompatibility complex I (MHC-1) presents antigenic peptides to tumor-specific CD8+ T cells. The regulation of MHC-I by kinases is largely unstudied, even though many patients with cancer are receiving therapeutic kinase inhibitors. Regulators of cell-surface HLA amounts were discovered using a pooled human kinome shRNA interference–based approach. Hits scoring highly were subsequently validated by additional RNAi and pharmacologic inhibitors. MAP2K1 (MEK), EGFR, and RET were validated as negative regulators of MHC-I expression and antigen presentation machinery in multiple cancer types, acting through an ERK output–dependent mechanism; the pathways responsible for increased MHC-I upon kinase inhibition were mapped. Activated MAPK signaling in mouse tumors in vivo suppressed components of MHC-I and the antigen presentation machinery. Pharmacologic inhibition of MAPK signaling also led to improved peptide/MHC target recognition and killing by T cells and TCR-mimic antibodies. Druggable kinases may thus serve as immediately applicable targets for modulating immunotherapy for many diseases. Cancer Immunol Res; 4(11); 936–47. ©2016 AACR.
This paper references
Multiple sclerosis: a modifying influence of HLA class I genes in an HLA class II associated autoimmune disease.
A. Fogdell-Hahn (2000)
The Two Faces of Interferon-γ in Cancer
M. Zaidi (2011)
Epidermal Growth Factor Receptor Inhibition Augments the Expression of MHC Class I and II Genes
B. Pollack (2011)
Quantitative correlation between HLA class I allele expression and recognition of melanoma cells by antigen-specific cytotoxic T lymphocytes.
L. Rivoltini (1995)
Regulation of human β2-microglobulin transactivation in hematopoietic cells
S. Gobin (2003)
Cancer Regression in Patients After Transfer of Genetically Engineered Lymphocytes
R. Morgan (2006)
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
L. Liu (2015)
Improved survival with MEK inhibition in BRAF-mutated melanoma.
K. Flaherty (2012)
Down-regulation of HLA class I antigen-processing molecules in malignant melanoma: association with disease progression.
T. Kageshita (1999)
An optimized microRNA backbone for effective single-copy RNAi.
Christof Fellmann (2013)
The RFX complex is crucial for the constitutive and CIITA-mediated transactivation of MHC class I and beta2-microglobulin genes.
S. Gobin (1998)
Quantitative correlation between HLA class I allele expression and recognition ofmelanoma cells by antigen-specific cytotoxic T lymphocytes
L Rivoltini (1995)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
E. V. Van Allen (2015)
Induction of HLA class I mRNA by cytokines in human fibroblasts: comparison of TNF, IL-1 and IFN-beta.
J. Wolchok (1992)
The blockade of immune checkpoints in cancer immunotherapy
D. Pardoll (2012)
Combining Epigenetic and Immunotherapy to Combat Cancer.
Katherine B. Chiappinelli (2016)
Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi
J. Zuber (2011)
Activation of NF‐κB may be necessary but is not sufficient for induction of H‐2 antigens by TNF in J558L murine myeloma cells
J. Wolchok (1994)
Inflammatory skin diseases, T cells, and immune surveillance.
C. Robert (1999)
Therapeutic Efficacy of an Fc-Enhanced TCR-like Antibody to the Intracellular WT1 Oncoprotein
N. Veomett (2014)
induction cells of NF-xB may be necessary but is not sufficient for of H-2 antigens by TNF in J558L murine myeloma
D Wolchok (1994)
Paradoxical Activation of T Cells via Augmented ERK Signaling Mediated by a RAF Inhibitor
M. Callahan (2013)
MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade.
P. J. Ebert (2016)
Down-regulation ofHLA class I antigen-processing molecules in malignant melanoma
T Kageshita (1999)
Genetics of ankylosing spondylitisinsights into pathogenesis
MA Brown (2016)
The kinase inhibitors dabrafenib and trametinib affect isolated immune cell populations
L. J. Vella (2014)
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
D. Cross (2014)
A Therapeutic TCR Mimic Monoclonal Antibody for Intracellular PRAME Protein in Leukemias
Aaron Y. Chang (2015)
Lung adenocarcinomas induced in mice by mutant EGF receptors found in human lung cancers respond to a tyrosine kinase inhibitor or to down-regulation of the receptors.
K. Politi (2006)
Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAFV600E melanoma
S. Hu-Lieskovan (2015)
HLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance
M. Campoli (2008)
Big opportunities for small molecules in immuno-oncology
J. Adams (2015)
Transferred WT1-Reactive CD8+ T Cells Can Mediate Antileukemic Activity and Persist in Post-Transplant Patients
Aude G Chapuis (2013)
Cancer immunotherapy comes of age
I. Mellman (2011)
MEK Inhibition, Alone or in Combination with BRAF Inhibition, Affects Multiple Functions of Isolated Normal Human Lymphocytes and Dendritic Cells
L. J. Vella (2014)
Genetic basis for clinical response to CTLA-4 blockade in melanoma.
A. Snyder (2014)
Scheinberg Acquisition of data (provided animals, acquired and managed patients, provided facilities
E J Brea
Coactivation of Receptor Tyrosine Kinases in Malignant Mesothelioma as a Rationale for Combination Targeted Therapy
M. Brevet (2011)
CD8+ T cell concentration determines their efficiency in killing cognate antigen–expressing syngeneic mammalian cells in vitro and in mouse tissues
Sadna Budhu (2010)
WT1 peptide vaccinations induce CD4 and CD8 T cell immune responses in patients with mesothelioma and non-small cell lung cancer
L. Krug (2010)
Transcriptional regulation of HLA-A and -B: differential binding of members of the Rel and IRF families of transcription factors.
J. Girdlestone (1993)
Targeting the Intracellular WT1 Oncogene Product with a Therapeutic Human Antibody
T. Dao (2013)
MHC class I gene expression and regulation.
S. Agrawal (2000)
Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer.
Lucía Regales (2009)
Improved survival with MEK Inhibition in BRAF-mutated melanoma for the METRIC Study Group
K. Flaherty (2012)
BRAF mutation predicts sensitivity to MEK inhibition
D. Solit (2006)
A Genome-wide Multidimensional RNAi Screen Reveals Pathways Controlling MHC Class II Antigen Presentation
Petra Paul (2011)
Genetics of ankylosing spondylitis—insights into pathogenesis
M. Brown (2016)
The MAPK Pathway Is a Predominant Regulator of HLA-A Expression in Esophageal and Gastric Cancer
K. Mimura (2013)
MHC class I antigen processing and presenting machinery: organization, function, and defects in tumor cells.
P. Leone (2013)
Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: In vivo persistence, migration, and antitumor effect of transferred T cells
C. Yee (2002)
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
N. Rizvi (2015)
Role of non-classical MHC class I molecules in cancer immunosuppression
G. Kochan (2013)
Ras and extracellular signal-regulated kinase signaling in thymocytes and T cells.
R. Kortum (2013)
Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial.
L. Calabrò (2013)
Activation of the PD-1 pathway contributes to immune escape in EGFR-driven lung tumors.
E. Akbay (2013)
This paper is referenced by
Gene signature of antigen processing and presentation machinery predicts response to checkpoint blockade in non-small cell lung cancer (NSCLC) and melanoma
J. C. Thompson (2020)
The immune contexture in cancer prognosis and treatment
Wolf H. Fridman (2017)
The MEK Inhibitor Trametinib Suppresses Major Histocompatibility Antigen-mismatched Rejection Following Pancreatic Islet Transplantation
Seiichiro Tada (2020)
Phosphoinositide 3-Kinase Signaling Can Modulate MHC Class I and II Expression
S. Chandrasekaran (2019)
Contemporary Tailored Oncology Treatment of Biliary Tract Cancers
F. Turkes (2019)
MAPK pathway activity plays a key role in PD‐L1 expression of lung adenocarcinoma cells
T. Stutvoet (2019)
Targeting RET-driven cancers: lessons from evolving preclinical and clinical landscapes
A. Drilon (2018)
Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities in Pancreas Cancer
M. Ruscetti (2020)
Pulsatile MEK Inhibition Improves Anti-tumor Immunity and T Cell Function in Murine Kras Mutant Lung Cancer
H. Choi (2019)
Tumor-intrinsic PIK3CA represses tumor immunogenicity in a model of pancreatic cancer
N. Sivaram (2019)
Transbronchoscopic patient biopsy-derived xenografts as a preclinical model to explore chemorefractory-associated pathways and biomarkers for small-cell lung cancer.
Z. Wang (2019)
The TAM family as a therapeutic target in combination with radiation therapy
G. Tormoen (2017)
Targeting innate sensing in the tumor microenvironment to improve immunotherapy
Zhida Liu (2019)
Tumor-intrinsic PIK 3 CA represses tumor immunogenicity in a model of pancreatic cancer
Nithya Sivaram (2019)
Targeting Protein Kinases to Enhance the Response to anti-PD-1/PD-L1 Immunotherapy
M. García-Aranda (2019)
Restoration of immune surface molecules in Kaposi sarcoma-associated herpesvirus infected cells by lenalidomide and pomalidomide.
D. Davis (2017)
HER1-based vaccine: Simultaneous activation of humoral and cellular immune response.
G. B. Báez (2018)
Improving cancer‐specific outcomes in solid organ transplant recipients: Where to begin?
J. Koff (2019)
Regorafenib Promotes Antitumor Immunity via Inhibiting PD-L1 and IDO1 Expression in Melanoma
Ruiyan Wu (2019)
Neuroblastoma rat sarcoma mutated melanoma: That’s what we got so far
Elisa Bertoli (2019)
The MAPK hypothesis: immune-regulatory effects of MAPK-pathway genetic dysregulations and implications for breast cancer immunotherapy
D. Bedognetti (2017)
Elimination of melanoma by sortase A-generated TCR-like antibody-drug conjugates (TL-ADCs) targeting intracellular melanoma antigen MART-1.
J. Lai (2018)
Multiplexed relative and absolute quantitative immunopeptidomics reveals MHC I repertoire alterations induced by CDK4/6 inhibition
Lauren E. Stopfer (2020)
MEK inhibition and immune responses in advanced melanoma
R. Dummer (2017)
Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies.
Roberta Zappasodi (2018)
Personalized neoantigen vaccination with synthetic long peptides: recent advances and future perspectives
X. Chen (2020)
Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients
F. Sabbatino (2020)
Cerebrospinal fluid lymphocytosis: a hallmark of neurological complications during checkpoint inhibition.
Ehj Erwin Tonk (2019)
The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironment
E. Poon (2017)
Low-Dose CDK4/6 Inhibitors Induce Presentation of Pathway Specific MHC ligands as Targets for Cancer Immunotherapy
Ángel Charles (2020)
Therapeutic opportunity in innate immune response induction by oncogene-targeted drugs.
Daniel J Sisler (2019)
oHSV therapy increases trametinib access to brain tumors and sensitizes them in vivo.
J. Yoo (2019)See more